These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Acute bilateral uveitis and right macular edema induced by a single infusion of zoledronic acid for the treatment of postmenopausal osteoporosis as a substitution for oral alendronate: a case report. Tian Y, Wang R, Liu L, Ma C, Lu Q, Yin F. BMC Musculoskelet Disord; 2016 Feb 11; 17():72. PubMed ID: 26867651 [Abstract] [Full Text] [Related]
24. [Factors associated with acute febrile reaction in elderly patients receiving intravenous zoledronic acid for osteoporosis]. Deng HO, Li DF, Zhang WJ, Zhi XM, Xu L, Wu W. Nan Fang Yi Ke Da Xue Xue Bao; 2011 Dec 11; 31(12):2076-8. PubMed ID: 22200716 [Abstract] [Full Text] [Related]
26. [Influence of history of oral bisphosphonates on the incidence rate of fever after intravenous injection of zoledronic acid in patients with osteoporosis]. Wang H, Hu ZH, Chen L, Pan Y. Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Aug 18; 48(4):680-682. PubMed ID: 29263512 [Abstract] [Full Text] [Related]
27. Management of osteoporosis in the aging male: focus on zoledronic acid. Piper PK, Gruntmanis U. Clin Interv Aging; 2009 Aug 18; 4():289-303. PubMed ID: 19750231 [Abstract] [Full Text] [Related]
28. [Zoledronic acid for preventing fractures. HORIZON trial (Health Outcomes and Reduced Incidence with Zoledronic acid ONce yearly)]. Ringe JD, Nitschmann S. Internist (Berl); 2008 Apr 18; 49(4):502-4. PubMed ID: 18305914 [No Abstract] [Full Text] [Related]
29. [Fracture prevention in postmenopausal women with osteoporosis by an annual infusion of zoledronic acid]. Geusens PP, Lems WF. Ned Tijdschr Geneeskd; 2007 Jun 30; 151(26):1445-8. PubMed ID: 17633971 [Abstract] [Full Text] [Related]
32. Respiratory complications associated with IV zoledronic acid infusion in the treatment of postmenopausal osteoporosis. Taggart H, Cheng J, Archbold P. Osteoporos Int; 2010 Sep 30; 21(9):1621-2. PubMed ID: 19813042 [No Abstract] [Full Text] [Related]
33. Severe non-infective systemic inflammatory response syndrome, shock, and end-organ dysfunction after zoledronic acid administration in a child. Trivedi S, Al-Nofal A, Kumar S, Tripathi S, Kahoud RJ, Tebben PJ. Osteoporos Int; 2016 Jul 30; 27(7):2379-2382. PubMed ID: 26892041 [Abstract] [Full Text] [Related]
34. Zoledronate Induced Hypocalcemia and Hypophosphatemia in Osteoporosis: A Cause of Concern. Kaur U, Chakrabarti SS, Gambhir IS. Curr Drug Saf; 2016 Jul 30; 11(3):267-9. PubMed ID: 27113952 [Abstract] [Full Text] [Related]
35. Diffuse ocular and orbital inflammation after zoledronate infusion-case report and review of the literature. Umunakwe OC, Herren D, Kim SJ, Kohanim S. Digit J Ophthalmol; 2017 Jul 30; 23(4):18-21. PubMed ID: 29403337 [Abstract] [Full Text] [Related]
36. Seizures associated with zoledronic acid for osteoporosis. Tsourdi E, Rachner TD, Gruber M, Hamann C, Ziemssen T, Hofbauer LC. J Clin Endocrinol Metab; 2011 Jul 30; 96(7):1955-9. PubMed ID: 21508139 [Abstract] [Full Text] [Related]
37. Subtrochanteric fracture in a patient receiving zoledronic acid therapy for metastatic breast cancer. Kishimoto Y, Iwase T, Koyama A, Masui T, Yoshida G, Matsuo H, Ishiguro N. Nagoya J Med Sci; 2011 Aug 30; 73(3-4):211-5. PubMed ID: 21928703 [Abstract] [Full Text] [Related]
38. Annual zoledronic acid for osteoporosis. BMJ Group. Drug Ther Bull; 2008 Dec 30; 46(12):93-6. PubMed ID: 19056701 [Abstract] [Full Text] [Related]